Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Alnylam Pharmaceuticals, Inc. $387.5 Million Common Stock Offering
Davis Polk advised the sole book-running manager of a $387.5 million SEC-registered offering of 5,000,000 shares of common…
Bristol-Myers Squibb Acquires Celgene
Davis Polk is advising Morgan Stanley & Co. LLC, Evercore and Dyal Co. LLC as financial advisers to Bristol-Myers Squibb…
The Medicines Company $150 Million Convertible Notes Offering
Davis Polk advised the sole initial purchaser in connection with a Rule 144A offering by The Medicines Company of $150…
Hologic, Inc. $3 Billion Senior Secured Credit Facilities Refinancing
Davis Polk advised the administrative agent and the lenders in connection with the refinancing of Hologic, Inc.’s existing…
Secondary Offering of NeoGenomics, Inc. Common Stock
Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of…
Davis Polk Advises Notre Dame Intermédica on Its R$2.7 Billion Equity Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame…
Davis Polk Advises Nutrisystem on Its Acquisition by Tivity Health
Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is…
Davis Polk Advises Mereo BioPharma Group plc on Its Combination with OncoMed Pharmaceuticals, Inc.
Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction,…
DexCom, Inc. $850 Million Convertible Notes Offering
Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc…
Taiwan Liposome Company, Ltd. Initial Public Offering
Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public…